updated 1/3/2011 9:16:01 AM ET 2011-01-03T14:16:01

SCHOFIELD, Wis., Jan. 3, 2011 (GLOBE NEWSWIRE) -- PuraMed BioScience, Inc. (OTCQB:PMBS) announced today that the manuscript of the clinical study of LipiGesic™ M has been completed and has been submitted to a top-ranked medical journal for peer review.

In an effort to maximize the potential for publication, an embargo has been placed on the disclosure of the manuscript or any of the results of this study. The clinical study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic™ M for the treatment of acute migraine attacks.

"We are very pleased to announce that the manuscript from clinical study on LipiGesic™ M has been completed," said PuraMed BioScience CEO Russell Mitchell. "This is another milestone that we have achieved based on the model we laid out in our business plan. We look forward to the next steps in this process, which include acceptance from the journal and actual publication."

Mitchell continued, "We anticipate the moment when study results will become publicly available, as we feel the study may provide us with objective scientific data which can help describe the efficacy of LipiGesic™ M, how it should be properly used and perhaps new labeling opportunities that could increase product visibility not only to the medical community, but the general public as well. We also continue to identify national retail opportunities in order to prepare for the retail launch of LipiGesic™ M."

Currently, LipiGesic™ M may be purchased by calling 877-851-2190 or visiting www.mymigrainegone.com or www.lipigesic.com . The Company's two-minute direct response television commercial is available for viewing on these websites as well.

About PuraMed BioScience, Inc.:

PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic™ M, which provides acute relief from migraine headaches, the Company also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic™ H for tension-type headaches. For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com , join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at www.twitter.com/puramed .

Forward Looking Statements:

This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

CONTACT:  PuraMed BioScience, Inc.
          Russell Mitchell, Chairman and CEO
          715-359-6373
          rmitchell@PuraMedBioScience.com
          www.PuraMedBioScience.com

          Investor Awareness, Inc.
          Investor Relations:
          Tony Schor
          James Foy
          847-945-2222
          www.investorawareness.com

          North Shore Public Relations, Inc.
          Media Contact:
          Renae Placinski
          847-945-4505
          renae@northshorepr.com 
          www.northshorepr.com

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.71%
$30K home equity loan FICO 5.26%
$75K home equity loan FICO 4.70%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.42%
13.42%
Cash Back Cards 17.94%
17.94%
Rewards Cards 17.14%
17.14%
Source: Bankrate.com